COVID-19 RT-qPCR Assay Mitigates Risk for Biopharmaceuticals
Charles River has developed an assay to lower the risks associated with COVID-19 in the production and manufacturing of your product. To help mitigate these risks, our SARS-CoV-2-specific, real-time reverse transcription polymerase chain reaction (RT-qPCR) assay is combined with commercially available isolation kits and tailored to viral nucleic acid recovery in order to screen starting materials, safeguard cell substrates, and test final products.
SARS-CoV-2 consists of a number of structural proteins encoded by its single-strand RNA genome, including envelope (E), envelope glycoprotein spike (S), transmembrane (M), helicase (Hel), and nucleocapsid (N). In addition to these structural protein-encoding genes, there are species-specific accessory genes that are required for viral replication, including RNA-dependent RNA polymerase (RdRp), hemagglutinin esterase (HE), and open reading frames ORF1a and ORF1b.
This RT-qPCR assay is specifically targeted to different regions of SARS-CoV-2 genomic RNA.
COVID-19 Research Support
Discover how Charles River can help you meet the needs of patients waiting for testing and treatment.
Over the years, qPCR has proven to be a well-established platform for the detection and quantification of adventitious viruses from many sample types and buffer matrixes through the use of various commercially available extraction kits. RT-qPCR can efficiently target and amplify a minute amount of viral nucleic acid in real time by using fluorescent reporter dye.
The COVID-19 pandemic could negatively impact the supply chain and biomanufacturing of biopharmaceuticals, including cell and gene therapy products. Our team is here to answer your questions and discuss how this assay may help mitigate these risks.